NCT04305444 2025-01-08
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Phase 2 Terminated
Clinical Trials
13 trialsNCT01665768 2021-10-26
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00702052 2021-05-25
PILLAR-1
Novartis
Phase 2 Completed
NCT02113800 2020-10-28
EVINEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT00436618 2019-10-22
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Mayo Clinic
Phase 2 Completed
NCT00976248 2018-10-03
Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01637090 2017-01-12
CTCL
Boston Medical Center
Phase 2 Terminated
NCT00978432 2016-11-25
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Duke University
Phase 2 Terminated
NCT01022996 2016-05-18
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Novartis
Phase 2 Completed
NCT00516412 2015-09-29
Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Swiss Cancer Institute
Phase 2 Completed
NCT00869999 2014-10-27
Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT01164267 2013-11-25
Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Completed
NCT00727207 2012-12-17
Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy
Technical University of Munich
Phase 2 Terminated